GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Debt-to-Revenue

Molecular Partners AG (XSWX:MOLN) Debt-to-Revenue : 0.89 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Molecular Partners AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF1.21 Mil. Molecular Partners AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF2.44 Mil. Molecular Partners AG's annualized Revenue for the quarter that ended in Dec. 2023 was CHF4.13 Mil. Molecular Partners AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.88.


Molecular Partners AG Debt-to-Revenue Historical Data

The historical data trend for Molecular Partners AG's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Debt-to-Revenue Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.77 0.65 0.03 0.52

Molecular Partners AG Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.37 2.56 0.39 0.89

Competitive Comparison of Molecular Partners AG's Debt-to-Revenue

For the Biotechnology subindustry, Molecular Partners AG's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Debt-to-Revenue falls into.



Molecular Partners AG Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Molecular Partners AG's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.208 + 2.444) / 7.038
=0.52

Molecular Partners AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.208 + 2.444) / 4.128
=0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Molecular Partners AG Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

By Stock market mentor Stock market mentor 01-08-2023